Company intelligence / Profile preview

DBL Pharmaceuticals

Dhaka, Dhaka, Bangladeshdbl-pharma.com ↗

Ownership: Private
Employees: ~340
Development stage: Commercial

Overview

DBL Pharma has rapidly established itself as a significant player in both the Bangladeshi and US generic pharmaceutical markets. It became the second largest seller of Methocarbamol tablets in the US within two years of launch. The company emphasizes advanced manufacturing standards compliant with WHO cGMP, US FDA, UK MHRA regulations. Recent launches include technologically advanced inhalers for asthma/COPD management.

Therapeutic areas: PulmonologyEndocrinologyImmunologyCardiovascularNeurologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

5 assets

telmisartan

Commercial

Indications: Hypertension

4 more assets in the full pipeline.

Request access →

Partnerships

ROMACO KILIANBOSCH

Beyond the preview

Go deeper on DBL Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DBL Pharmaceuticals.

Explore the full profile